Virios therapeutics announces completion of enrollment in imc-2 phase 2 long-covid study being conducted by bateman horne center

- virios projects releasing top line results from this groundbreaking proof of concept study in october 2024 - - published data indicates increased epstein-barr herpes virus in long-covid patients, highlighting potential for antiviral therapy to treat fatigue and other long-covid symptoms - atlanta, july 23, 2024 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”) and long-covid (“lc”), today announced that the bateman horne center (“bhc”) has completed enrollment in its investigator-initiated, proof of concept lc study. top line data from this study are projected to be released in october 2024.
VIRI Ratings Summary
VIRI Quant Ranking